Literature DB >> 17262045

Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram.

A L Potts1, K L Young, B S Carter, J P Shenai.   

Abstract

A term neonate presenting with necrotizing enterocolitis following in utero and breast milk exposure to the newest serotonin selective reuptake inhibitor, escitalopram, is described.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17262045     DOI： 10.1038/sj.jp.7211640

Source DB:  PubMed          Journal:  J Perinatol        ISSN： 0743-8346            Impact factor:   2.521


  6 in total

Review 1.  Depression During Pregnancy and Postpartum.

Authors:  Madeleine Becker; Tal Weinberger; Ann Chandy; Sarah Schmukler
Journal:  Curr Psychiatry Rep       Date:  2016-03       Impact factor: 5.285

2.  Antenatal Escitalopram Use and Necrotizing Enterocolitis in a Newborn: A Case Report.

Authors:  Nilima Jawale; Alok Bhutada; Shantanu Rastogi
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Nov-Dec

Review 3.  Antidepressant medication use during breastfeeding.

Authors:  Teresa Lanza di Scalea; Katherine L Wisner
Journal:  Clin Obstet Gynecol       Date:  2009-09       Impact factor: 2.190

4.  Use of escitalopram during pregnancy: navigating towards international guidelines and the real world.

Authors:  Salvatore Gentile
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

5.  Global hypoxia-ischemia induced inflammation and structural changes in the preterm ovine gut which were not ameliorated by mesenchymal stem cell treatment.

Authors:  Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs
Journal:  Mol Med       Date:  2016-04-14       Impact factor: 6.354

Review 6.  Management of postpartum depression.

Authors:  Constance Guille; Roger Newman; Leah D Fryml; Clay K Lifton; C Neill Epperson
Journal:  J Midwifery Womens Health       Date:  2013-10-16       Impact factor: 2.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.